Summary
Abbott Laboratories (ABT) filed an 8-K on July 18, 2012, to announce its second-quarter 2012 financial results. The filing primarily serves to furnish a press release containing these results. Notably, the company disclosed its use of non-GAAP financial measures, such as net earnings and diluted earnings per share excluding specified items. These adjustments are made for factors considered unusual or unpredictable, including acquisition-related costs, separation costs, milestone payments, litigation reserves, restructuring and integration charges, and other one-time events. Management indicated that these non-GAAP measures are employed internally for performance monitoring and are presented to investors to offer a clearer view of ongoing business performance. However, Abbott cautioned investors to consider these non-GAAP figures alongside, and not as a replacement for, their GAAP-compliant financial statements. The filing also lists the press release as Exhibit 99.1.
Key Highlights
- 1Abbott Laboratories reported its second-quarter 2012 financial results on July 18, 2012, via an 8-K filing.
- 2The primary purpose of the 8-K was to furnish a press release containing the company's Q2 2012 earnings.
- 3Abbott utilized non-GAAP financial measures, including net earnings and EPS, adjusted for specific items.
- 4Adjusted items mentioned include acquisition/separation costs, milestone payments, litigation reserves, and restructuring charges.
- 5Management believes these non-GAAP measures provide better insight into ongoing operational performance.
- 6Investors are advised to view non-GAAP measures as supplementary to, not a substitute for, GAAP results.
- 7The press release detailing the Q2 2012 results is provided as Exhibit 99.1 to the filing.